ATE459644T1 - Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung - Google Patents

Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung

Info

Publication number
ATE459644T1
ATE459644T1 AT03763948T AT03763948T ATE459644T1 AT E459644 T1 ATE459644 T1 AT E459644T1 AT 03763948 T AT03763948 T AT 03763948T AT 03763948 T AT03763948 T AT 03763948T AT E459644 T1 ATE459644 T1 AT E459644T1
Authority
AT
Austria
Prior art keywords
seq
cosmetics
areas
treatment
aspartic proteases
Prior art date
Application number
AT03763948T
Other languages
English (en)
Inventor
Dominique Bernard
Bruno Mehul
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oreal filed Critical Oreal
Application granted granted Critical
Publication of ATE459644T1 publication Critical patent/ATE459644T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
AT03763948T 2002-07-09 2003-07-09 Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung ATE459644T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0208613A FR2842209B1 (fr) 2002-07-09 2002-07-09 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
PCT/FR2003/002151 WO2004007548A1 (fr) 2002-07-09 2003-07-09 Utilisation de proteases aspartiques dans le domaine cosmetique et therapeutique

Publications (1)

Publication Number Publication Date
ATE459644T1 true ATE459644T1 (de) 2010-03-15

Family

ID=29763673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03763948T ATE459644T1 (de) 2002-07-09 2003-07-09 Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung

Country Status (10)

Country Link
US (2) US7521422B2 (de)
EP (1) EP1519952B1 (de)
JP (1) JP4459808B2 (de)
AT (1) ATE459644T1 (de)
AU (1) AU2003264708A1 (de)
CA (1) CA2491080A1 (de)
DE (1) DE60331546D1 (de)
ES (1) ES2340481T3 (de)
FR (1) FR2842209B1 (de)
WO (1) WO2004007548A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842209B1 (fr) * 2002-07-09 2007-11-23 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
KR101165848B1 (ko) * 2005-08-18 2012-07-13 (주)아모레퍼시픽 효소 및 아미노산을 함유하는 피부 화장료 조성물
EP1935243B1 (de) * 2005-10-11 2014-05-14 Eisai R&D Management Co., Ltd. SASPase-Knockout-Maus
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
BRPI0922969A2 (pt) 2008-12-19 2019-09-24 Univ Indiana Res & Tech Corp pró-farmaco de amida baseado na superfamília de glucagon peptídeo.
CA2747195A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
CA2744558A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
AU2009335712B2 (en) 2008-12-19 2015-09-17 Indiana University Research And Technology Corporation Insulin analogs
US20110076333A1 (en) * 2009-09-25 2011-03-31 Susan Daly Method and compositions for selectively treating skin
CN103068842B (zh) 2010-06-16 2016-10-19 印第安纳大学研究及科技有限公司 对胰岛素受体具有高活性的单链胰岛素激动剂
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
WO2011163462A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
FR2968199B1 (fr) * 2010-12-07 2013-01-18 Oreal Agents modulateurs du complexe saspase-flg2 et peaux grasses
FR2968200B1 (fr) * 2010-12-07 2013-01-18 Oreal Agents modulateurs du complexe saspase-flg2 et utilisations
FR2968303B1 (fr) * 2010-12-07 2013-01-18 Oreal Peptides modulateurs du complexe saspase-flg2
FR2968201B1 (fr) 2010-12-07 2017-07-21 Oreal Complexe saspase-flg2, agents modulateurs et utilisations
EP2793932B1 (de) * 2011-12-20 2018-10-03 Indiana University Research and Technology Corporation Insulinanaloga auf ctp-basis zur behandlung von diabetes
FR2991680B1 (fr) * 2012-06-06 2014-09-05 Oreal Composes pour application anti-age et peau seche
EP2900255B1 (de) 2012-09-26 2019-01-30 Indiana University Research and Technology Corporation Insulin-analoge dimere
CA2904332A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
GB201305023D0 (en) 2013-03-19 2013-05-01 Biocant Associa O De Transfer Ncia De Tecnologia Aspartic proteases
CN107001441A (zh) 2014-09-24 2017-08-01 印第安纳大学研究及科技有限公司 脂质化的基于酰胺的胰岛素前药
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
WO2019014744A1 (en) * 2017-07-17 2019-01-24 Universite Laval ASPRV1 AS A NEUTROPHIL SPECIFIC MARKER AND THERAPEUTIC TARGET FOR INFLAMMATORY DISEASES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319104D0 (en) * 1993-09-15 1993-11-03 Unilever Plc Skin care method & composition
FR2761363B1 (fr) * 1997-03-28 1999-11-26 Oreal Polypeptide purifie de l'epiderme et son utilisation
FR2767833B1 (fr) 1997-08-29 2001-03-02 Oreal Polypeptide isole de l'epiderme et son utilisation
DE19950020A1 (de) 1999-10-16 2001-04-19 Henkel Kgaa Verwendung von Zusammensetzungen zur pflegenden Behandlung der Haut
GB0004312D0 (en) 2000-02-23 2000-04-12 Oxagen Limited Test and model for inflammatory disease
WO2002022101A1 (en) 2000-09-13 2002-03-21 The Procter & Gamble Company Cosmetic method
US20030206896A1 (en) * 2000-09-13 2003-11-06 O'prey Conor James Cosmetic method
JP2003088388A (ja) * 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
FR2842209B1 (fr) * 2002-07-09 2007-11-23 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique

Also Published As

Publication number Publication date
CA2491080A1 (fr) 2004-01-22
US7521422B2 (en) 2009-04-21
AU2003264708A1 (en) 2004-02-02
JP4459808B2 (ja) 2010-04-28
ES2340481T3 (es) 2010-06-04
WO2004007548A1 (fr) 2004-01-22
EP1519952B1 (de) 2010-03-03
US20090186821A1 (en) 2009-07-23
FR2842209A1 (fr) 2004-01-16
US20060240053A1 (en) 2006-10-26
EP1519952A1 (de) 2005-04-06
JP2006511204A (ja) 2006-04-06
FR2842209B1 (fr) 2007-11-23
US7888315B2 (en) 2011-02-15
DE60331546D1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
ATE459644T1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
ATE333888T1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
DE60225118D1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
DE69412243D1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
DE69326776T2 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
NO962664D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
ATE267249T1 (de) Aus dem epidermis isolierte polypeptide und verwendung davon
DE60040623D1 (de) Komplementäre, synthetische peptide und ihre nutzung in der ophthalmologie
DE69938786D1 (de) Die verwendung von peptiden von il-2 und peptid-derivaten als therapeutische wirkstoffe
DE60045681D1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
ATE363531T1 (de) Claudin polypeptide
MXPA02000465A (es) Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6.
ATE364079T1 (de) Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung
DE69823501D1 (de) Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin-abhängiger krankheiten
FI973221A0 (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
ATE438658T1 (de) Neue polypeptide aus bienengift und dessen gebrauchsverfahren
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE361914T1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
DK0842193T3 (da) Somatostatin-analoge cykliske peptider med hæmmende aktivitet på væksthormon
DE60135489D1 (de) Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung
DK1438329T3 (da) Biologisk aktive peptider og deres anvendelse til reparation af beskadigede nerver

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties